CC
VRTX icon

Centiva Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Centiva Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,147
Closed -$959K – 2239
2026
Q1 		$959K Buy
+2,147
New +$1M 0.01% 610
2025
Q2 		– Sell
-425
Closed -$206K – 2074
2025
Q1 		$206K Sell
425
-832
-66% -$388K 0.01% 1282
2024
Q4 		$506K Sell
1,257
-1,768
-58% -$820K 0.01% 815
2024
Q3 		$1.41M Buy
3,025
+138
+5% +$66.3K 0.03% 644
2024
Q2 		$1.35M Buy
2,887
+579
+25% +$251K 0.02% 623
2024
Q1 		$965K Buy
2,308
+1,314
+132% +$555K 0.02% 684
2023
Q4 		$404K Buy
994
+484
+95% +$179K 0.01% 1059
2023
Q3 		$177K Sell
510
-9,952
-95% -$3.48M ﹤0.01% 1407
2023
Q2 		$3.68M Buy
10,462
+9,723
+1,316% +$3.28M 0.08% 249
2023
Q1 		$233K Buy
739
+314
+74% +$94.2K 0.01% 1163
2022
Q4 		$123K Sell
425
-55
-11% -$16.8K ﹤0.01% 1165
2022
Q3 		$139K Buy
+480
New +$138K ﹤0.01% 1238
2021
Q3 		– Sell
-11,053
Closed -$2.23M – 1635
2021
Q2 		$2.23M Buy
11,053
+5,757
+109% +$1.2M 0.05% 296
2021
Q1 		$1.14M Buy
5,296
+1,615
+44% +$355K 0.04% 311
2020
Q4 		$870K Buy
3,681
+1,016
+38% +$233K 0.03% 307
2020
Q3 		$725K Sell
2,665
-2,176
-45% -$600K 0.05% 256
2020
Q2 		$1.41M Buy
4,841
+519
+12% +$141K 0.08% 137
2020
Q1 		$1.03M Sell
4,322
-8,552
-66% -$1.96M 0.05% 192
2019
Q4 		$2.82M Sell
12,874
-830
-6% -$168K 0.14% 143
2019
Q3 		$2.32M Buy
13,704
+12,496
+1,034% +$2.21M 0.14% 152
2019
Q2 		$221K Sell
1,208
-2,277
-65% -$398K 0.01% 333
2019
Q1 		$641K Buy
+3,485
New +$644K 0.04% 214

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Centiva Capital's VRTX Position: Q2 2026 in Review

Centiva Capital sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 2,147 shares — an estimated $959K sold.

Centiva Capital first reported a position in VRTX in Q1 2019 and held it in 22 quarters. The position peaked at $3.68M in Q2 2023. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Centiva Capital reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Centiva Capital sold 2,147 Vertex Pharmaceuticals shares in Q2 2026, an estimated $959K.
  • Centiva Capital first reported a position in Vertex Pharmaceuticals in Q1 2019 and held it in 22 quarters.
  • Centiva Capital's Vertex Pharmaceuticals position peaked at $3.68M in Q2 2023.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.